AI assistant
Sending…
Lineage Cell Therapeutics Inc. — Director's Dealing 2012
Apr 12, 2012
6895_dirs_2012-04-12_05ace209-b262-42fb-b0e3-7263e7021cc7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-04-11
Reporting Person: COHEN ABRAHAM E (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-04-11 | Common Shares, no par value | P | 10000 | $4.12 | Acquired | 10000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Shares | $5.13 | 2016-06-30 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $5.45 | 2015-08-09 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $2.30 | 2014-07-01 | Common Shares (20000) | 20000 | Direct |
Footnotes
F1: Does not include shares that may be acquired upon the exercise of certain stock options.
F2: 5,000 options became exercisable on September 30, 2011; December 31, 2011; and March 31, 2012. The remaining 5,000 options will become exercisable on June 30, 2012 based upon continued service on the board of directors.
F3: 5,000 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.
F4: 5,000 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.
More from Lineage Cell Therapeutics Inc.
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 13
Earnings Release
2026
May 13
Report Publication Announcement
2026
May 13
Report Publication Announcement
2026
May 13
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Report Publication Announcement
2026
May 5
Earnings Release
2026
May 5
Investor Presentation
2026
May 4